CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer

F. Loupakis, P. Biason, A.A. Prete, C. Cremolini, F. Pietrantonio, N. Pella, E. Dell’Aquila, E. Sperti, C. Zichi, R. Intini, V. Dadduzio, M. Schirripa, F. Bergamo, C. Antoniotti, F. Morano, F. Cortiula, G. De Maglio, L. Rimassa, V. Smiroldo, L. CalvettiG. Aprile, L. Salvatore, D. Santini, G. Munari, R. Salmaso, V. Guzzardo, C. Mescoli, S. Lonardi, M. Rugge, V. Zagonel, M. Di Maio, M. Fassan

Research output: Contribution to journalArticle


Background: V600EBRAF mutated metastatic colorectal cancer (mCRC) is a subtype (10%) with overall poor prognosis, but the clinical experience suggests a great heterogeneity in survival. It is still unexplored the real distribution of traditional and innovative biomarkers among V600EBRAF mutated mCRC and which is their role in the improvement of clinical prediction of survival outcomes. Methods: Data and tissue specimens from 155 V600EBRAF mutated mCRC patients treated at eight Italian Units of Oncology were collected. Specimens were analysed by means of immunohistochemistry profiling performed on tissue microarrays. Primary endpoint was overall survival (OS). Results: CDX2 loss conferred worse OS (HR = 1.72, 95%CI 1.03–2.86, p = 0.036), as well as high CK7 expression (HR = 2.17, 95%CI 1.10–4.29, p = 0.026). According to Consensus Molecular Subtypes (CMS), CMS1 patients had better OS compared to CMS2-3/CMS4 (HR = 0.37, 95%CI 0.19–0.71, p = 0.003). Samples showing less TILs had worse OS (HR = 1.72, 95%CI 1.16–2.56, p = 0.007). Progression-free survival analyses led to similar results. At multivariate analysis, CK7 and CMS subgrouping retained their significant correlation with OS. Conclusion: The present study provides new evidence on how several well-established biomarkers perform in a homogenousV600EBRAF mutated mCRC population, with important and independent information added to standard clinical prognosticators. These data could be useful to inform further translational research, for patients’ stratification in clinical trials and in routine clinical practice to better estimate patients’ prognosis. © 2019, The Author(s), under exclusive licence to Cancer Research UK.
Original languageEnglish
Pages (from-to)593-599
Number of pages7
JournalBritish Journal of Cancer
Issue number7
Publication statusPublished - Oct 2019


  • antineoplastic agent
  • B Raf kinase
  • bevacizumab
  • biological product
  • cyclin D1
  • cyclin dependent kinase 1
  • cytokeratin 20
  • cytokeratin 7
  • DNA mismatch repair protein MSH2
  • mismatch repair protein PMS2
  • MutL protein homolog 1
  • protein MSH6
  • transcription factor Cdx2
  • aged
  • Article
  • cancer chemotherapy
  • cancer prognosis
  • cancer staging
  • cancer survival
  • clinical practice
  • controlled study
  • female
  • follow up
  • human
  • immunohistochemistry
  • major clinical study
  • male
  • metastatic colorectal cancer
  • monotherapy
  • overall survival
  • primary tumor
  • priority journal
  • progression free survival
  • protein depletion
  • protein expression
  • tissue microarray

Fingerprint Dive into the research topics of 'CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this

    Loupakis, F., Biason, P., Prete, A. A., Cremolini, C., Pietrantonio, F., Pella, N., Dell’Aquila, E., Sperti, E., Zichi, C., Intini, R., Dadduzio, V., Schirripa, M., Bergamo, F., Antoniotti, C., Morano, F., Cortiula, F., De Maglio, G., Rimassa, L., Smiroldo, V., ... Fassan, M. (2019). CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer. British Journal of Cancer, 121(7), 593-599.